•  
  •  
  •  
  •  

2026-07-26 10:01:35

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • 3i Infotech Ltd receives order worth Rs. 4.83 crore
  • Electronics Mart India Expands National Capital Footprint with New Store Opening in Saket, New Delhi
  • Dodla Dairy Delivers Record Revenue of ₹1,197.9 Crore in Q1 FY27 Driven by VAP Surge and 45.6% Growth in Africa
  • NBCC Secures Domestic Work Orders Worth ₹108.85 Crore in Agriculture and Education Sectors
  • Kesar India Limited's Wholly Owned Subsidiary Acquires Commercial Office Space in Hyderabad

Keywords Selected:  Lupin

Research

  • Lupin - Q1FY23 Result Update - Margin disappointment continues - HOLD

Stock Report

  • Lupin Spins Out Two Oncology Programs to Kaveri Therapeutics to Advance its Oncology Strategy
  • Lupin Named Among World's Most Sustainable Companies by TIME and Statista
  • Lupin Receives EIR from U.S. FDA for its Somerset Facility with VAI Classification
  • Lupin announces EMA Approval for NaMuscla® Expansion for Pediatric Indication with New Strengths
  • Lupin receives Tentative Approval from U.S. FDA for Enzalutamide Tablets
  • Lupin Launches Azilsartan Medoxomil Tablets in the United States
  • Lupin Collaborates with ERN for Luforbec® (beclometasone/formoterol) pMDI Launch in Spain
  • Lupin receives approval from U.S. FDA for Ranluspec™ (ranibizumab) Injection
  • NATCO and Lupin receive approval from U.S. FDA for Eribulin Mesylate Injection
  • Lupin and Natco Receive Approval from U.S. FDA for Eribulin Mesylate Injection
  • Lupin's Ankleshwar Facility Receives EIR from U.S. FDA
  • Lupin receives China Approval for Oseltamivir Phosphate Oral Suspension
  • Lupin Receives U.S. FDA Approval for Famotidine Injection, USP
  • Lupin Ltd recommends dividend of Rs. 18
  • Lupin Ltd posts Q4FY26 consolidated PAT climbs to Rs. 1460.34 crores
  • Lupin Receives U.S. FDA Approval for Glycerol Phenylbutyrate Oral Liquid
  • Lupin Launches Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States
  • USFDA inspection at Somerset facility of Lupin Ltd
  • Lupin Pharmaceuticals, Inc, USA enters into settlement agreement with Humana Inc
  • Lupin Launches Dapagliflozin Tablets in the United States
  • Lupin announces approval of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States
  • Lupin Announces the Approval of Dapagliflozin Tablets in the United States
  • Lupin Completes Acquisition of VISUfarma
  • Lupin Receives Tentative Approval from U.S. FDA for Sugammadex Injection

Latest Post

  • 3i Infotech Ltd receives order worth Rs. 4.83 crore
  • Electronics Mart India Expands National Capital Footprint with New Store Opening in Saket, New Delhi
  • Dodla Dairy Delivers Record Revenue of ₹1,197.9 Crore in Q1 FY27 Driven by VAP Surge and 45.6% Growth in Africa
  • NBCC Secures Domestic Work Orders Worth ₹108.85 Crore in Agriculture and Education Sectors
  • Kesar India Limited's Wholly Owned Subsidiary Acquires Commercial Office Space in Hyderabad


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025